ES2948263T3 - Uso del ácido (S)-3-amino-4-(difluorometilenil) ciclopent-1-eno-1-carboxílico y compuestos relacionados, ácido (1s,3s)-3-amino-4-(difluorometiliden) ciclopentano-1-carboxílico en el tratamiento del síndrome del X frágil o del síndrome de temblor/ataxia asociado al X frágil - Google Patents

Uso del ácido (S)-3-amino-4-(difluorometilenil) ciclopent-1-eno-1-carboxílico y compuestos relacionados, ácido (1s,3s)-3-amino-4-(difluorometiliden) ciclopentano-1-carboxílico en el tratamiento del síndrome del X frágil o del síndrome de temblor/ataxia asociado al X frágil Download PDF

Info

Publication number
ES2948263T3
ES2948263T3 ES19815892T ES19815892T ES2948263T3 ES 2948263 T3 ES2948263 T3 ES 2948263T3 ES 19815892 T ES19815892 T ES 19815892T ES 19815892 T ES19815892 T ES 19815892T ES 2948263 T3 ES2948263 T3 ES 2948263T3
Authority
ES
Spain
Prior art keywords
amino
carboxylic acid
difluoromethyleneyl
ene
cyclopent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES19815892T
Other languages
English (en)
Spanish (es)
Inventor
Matthew During
Brett Abrahams
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ovid Therapeutics Inc
Original Assignee
Ovid Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ovid Therapeutics Inc filed Critical Ovid Therapeutics Inc
Application granted granted Critical
Publication of ES2948263T3 publication Critical patent/ES2948263T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ES19815892T 2018-06-07 2019-06-07 Uso del ácido (S)-3-amino-4-(difluorometilenil) ciclopent-1-eno-1-carboxílico y compuestos relacionados, ácido (1s,3s)-3-amino-4-(difluorometiliden) ciclopentano-1-carboxílico en el tratamiento del síndrome del X frágil o del síndrome de temblor/ataxia asociado al X frágil Active ES2948263T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862681913P 2018-06-07 2018-06-07
PCT/US2019/035934 WO2019236938A1 (en) 2018-06-07 2019-06-07 Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid and related compounds, (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and vigabatrin in the treatment of developmental disorders

Publications (1)

Publication Number Publication Date
ES2948263T3 true ES2948263T3 (es) 2023-09-07

Family

ID=68765508

Family Applications (1)

Application Number Title Priority Date Filing Date
ES19815892T Active ES2948263T3 (es) 2018-06-07 2019-06-07 Uso del ácido (S)-3-amino-4-(difluorometilenil) ciclopent-1-eno-1-carboxílico y compuestos relacionados, ácido (1s,3s)-3-amino-4-(difluorometiliden) ciclopentano-1-carboxílico en el tratamiento del síndrome del X frágil o del síndrome de temblor/ataxia asociado al X frágil

Country Status (12)

Country Link
US (3) US10813899B2 (cg-RX-API-DMAC10.html)
EP (1) EP3813816B1 (cg-RX-API-DMAC10.html)
JP (1) JP7387179B2 (cg-RX-API-DMAC10.html)
KR (1) KR102744830B1 (cg-RX-API-DMAC10.html)
CN (1) CN112770739B (cg-RX-API-DMAC10.html)
AU (1) AU2019280980B2 (cg-RX-API-DMAC10.html)
CA (1) CA3102786A1 (cg-RX-API-DMAC10.html)
ES (1) ES2948263T3 (cg-RX-API-DMAC10.html)
IL (2) IL279220B2 (cg-RX-API-DMAC10.html)
MX (2) MX2020013290A (cg-RX-API-DMAC10.html)
PL (1) PL3813816T3 (cg-RX-API-DMAC10.html)
WO (1) WO2019236938A1 (cg-RX-API-DMAC10.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019236938A1 (en) 2018-06-07 2019-12-12 Ovid Therapeutics Inc. Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid and related compounds, (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and vigabatrin in the treatment of developmental disorders
WO2020039262A1 (en) 2018-08-18 2020-02-27 Ftf Pharma Private Limited Pharmaceuticals solution for oral dosage
WO2024058812A1 (en) 2022-09-16 2024-03-21 Pyros Pharmaceuticals, Inc. Vigabatrin liquid pharmaceutical composition
IL322802A (en) 2023-02-17 2025-10-01 Ovid Therapeutics Inc Use of (s)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of gastrointestinal disorders and as an immunomodulatory agent
US20240285565A1 (en) 2023-02-17 2024-08-29 Ovid Therapeutics Inc. Use of (s)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of diabetes and pre-diabetes
US20260130878A1 (en) * 2024-11-12 2026-05-14 Ovid Therapeutics Inc. Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid in the treatment of pain

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6794413B1 (en) 2002-07-19 2004-09-21 Northwestern University Compounds and related methods for inhibition of γ-aminobutyric acid aminotransferase
WO2005120496A2 (en) 2004-05-24 2005-12-22 Regents Of The University Of California TREATING LEARNING DEFICITS WITH INHIBITORS OF HMG CoA REDUCTASE
WO2009033818A2 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
CA2790820A1 (en) 2010-02-25 2011-09-01 Northwestern University Use (1s,3s)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid as a gaba aminotransferse inhibitor
US20130230586A1 (en) 2010-10-02 2013-09-05 Link Research & Grants Corporation Treatment of Tinnitus and Related Auditory Dysfunctions
WO2013006857A1 (en) 2011-07-07 2013-01-10 The Children's Hospital Of Philadelphia Genetic alterations associated with autism and the autistic phenotype and methods of use thereof for the diagnosis and treatment of autism
WO2013112363A1 (en) 2012-01-27 2013-08-01 Catalyst Pharmaceutical Partners Method of treating tourette's disorder with gaba-aminotransferase inactivators
TW201606304A (zh) * 2013-09-09 2016-02-16 亞克柏拉有限公司 測定治療反應之方法
US20150224164A1 (en) 2013-11-26 2015-08-13 Neuren Pharmaceuticals Limited Treatment of autism spectrum disorders using glycyl-l-2-methylprolyl-l-glumatic acid
AU2015342801A1 (en) 2014-11-07 2017-05-18 Hadasit Medical Research Services And Development Ltd. Ornithine aminotransferase inhibition with GABA Analogues for treatment of hepatocellular carcinoma
US20170348232A1 (en) * 2016-06-07 2017-12-07 Ovid Therapeutics Inc. Formulations of gaboxadol for treatment of angelman syndrome, fragile x syndrome and fragile x-associated tremor/ataxia syndrome
CN108137484B (zh) * 2015-10-09 2021-02-12 西北大学 作为用于治疗癫痫、成瘾和肝细胞癌的gaba氨基转移酶灭活剂的化合物
US10632088B2 (en) 2016-10-10 2020-04-28 Northwestern University Inactivators of Toxoplasma gondii ornithine aminotransferase for treating toxoplasmosis and malaria
KR20240110989A (ko) * 2017-02-08 2024-07-16 오비드 테라퓨틱스 인크. 프라더-윌리 증후군 및 발작 장애들을 치료하는 방법들
US20200268711A1 (en) * 2017-11-14 2020-08-27 Sk Biopharmaceuticals Co., Ltd. Use Of Carbamate Compound For Reducing Or Treating Developmental Disorders Including Fragile X Syndrome, Angelman Syndrome Or Rett Syndrome
JP7475055B2 (ja) 2018-05-25 2024-04-26 ノースウェスタン ユニバーシティ (s)-3-アミノ-4-(ジフルオロメチレニル)シクロペンタ-1-エン-1-カルボン酸の合成法
WO2019236938A1 (en) 2018-06-07 2019-12-12 Ovid Therapeutics Inc. Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid and related compounds, (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and vigabatrin in the treatment of developmental disorders

Also Published As

Publication number Publication date
MX2020013290A (es) 2021-04-29
KR102744830B1 (ko) 2024-12-19
JP7387179B2 (ja) 2023-11-28
IL304270B2 (en) 2024-10-01
US20190374492A1 (en) 2019-12-12
IL304270B1 (en) 2024-06-01
IL279220B2 (en) 2023-12-01
KR20210035802A (ko) 2021-04-01
EP3813816A1 (en) 2021-05-05
CA3102786A1 (en) 2019-12-12
IL304270A (en) 2023-09-01
CN112770739B (zh) 2023-12-12
IL279220A (en) 2021-01-31
US11660277B2 (en) 2023-05-30
IL279220B1 (en) 2023-08-01
EP3813816A4 (en) 2021-06-23
US12285397B2 (en) 2025-04-29
AU2019280980B2 (en) 2025-02-27
EP3813816B1 (en) 2023-06-07
US10813899B2 (en) 2020-10-27
CN112770739A (zh) 2021-05-07
AU2019280980A1 (en) 2021-01-07
MX2023006497A (es) 2023-06-21
JP2021527053A (ja) 2021-10-11
WO2019236938A1 (en) 2019-12-12
US20230255914A1 (en) 2023-08-17
US20210100763A1 (en) 2021-04-08
EP3813816C0 (en) 2023-06-07
PL3813816T3 (pl) 2023-07-31

Similar Documents

Publication Publication Date Title
EP3813816B1 (en) Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid and related compounds, (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid in the treatment of fragile x syndrome or fragile x-associated tremor/ataxia syndrome
ES2733677T3 (es) Agentes terapéuticos para enfermedades neurodegenerativas
ES3021189T3 (en) Treatment of angelman syndrome with gaboxadol
JP2024516421A (ja) Mdma鏡像異性体
EP3579826B1 (en) Methods of treating cdkl5 disorders with the compound ov329
CA3153305A1 (en) Methods for treating neurological disorders with ?1a-ar partial agonists
ES3057584T3 (en) Therapeutic agents for use in the treatment of restless leg syndrome
CN112566641A (zh) 治疗和/或预防与年龄相关的神经变性的进展和/或发病的方法和组合物
ES2983441T3 (es) Acetil-leucina para su uso en el tratamiento de síndrome de las piernas inquietas
JP2017533967A (ja) システアミン組成物を用いるハンチントン病の処置方法
CN107735094A (zh) 胱氨酸‑谷氨酸转运蛋白的抑制剂的新用途
HK40050398A (en) Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid and related compounds, (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid in the treatment of fragile x syndrome or fragile x-associated tremor/ataxia syndrome
HK40050398B (en) Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid and related compounds, (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid in the treatment of fragile x syndrome or fragile x-associated tremor/ataxia syndrome
JP6738797B2 (ja) レット症候群治療薬
WO2020018779A1 (en) Use of phenylethylidenehydrazine to treat seizure disorders, developmental disorders, neurological disorders, behavioral disorders and addiction
TW202539621A (zh) 用於治療巴金森氏症的治療劑
WO2025162430A1 (zh) 一种药物联用及其在预防或治疗神经退行性疾病中的用途
HK40025173A (en) Therapeutic agents for use in the treatment of restless leg syndrome
HK40025173B (en) Therapeutic agents for use in the treatment of restless leg syndrome